PharmaChem Technologies (Grand Bahama) Ltd. broke ground for its new $120 million pharmaceutical manufacturing facility in Freeport, Grand Bahama.

Plant completion is expected in early 2019. This new facility is supported by Gilead Sciences Inc. The companies had partnered in 2005 when Gilead established a facility in The Bahamas to manufacture tenofovir disoproxil fumarate (tenofovir DF), the active drug substance in Gilead’s Viread, through a cooperative effort between PharmaChem Technologies, Gilead Sciences and the Grand Bahama Port Authority.

Source: Government of the Bahamas